Ensuring patient safety in clinical trials for treatment of acute stroke.
Becker
K J
KJ
Tirschwell
D L
DL
D002986:Clinical Trials as Topic / Q000592:standards*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006146:Guanidines / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012306:Risk; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D006146:Guanidines; D018696:Neuroprotective Agents; C079779:aptiganel; D010959:Tissue Plasminogen Activator